[EN] TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR1-ANTICORPS ANTI-ASGR ET UTILISATIONS ASSOCIÉES
申请人:SILVERBACK THERAPEUTICS INC
公开号:WO2021072203A1
公开(公告)日:2021-04-15
Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.
本发明揭示了用于治疗肝病(如肝癌和肝纤维化)的各种共轭物和其组合物。这些组合物包括共轭物,其中共轭物由特异于ASGR1或ASGR2的抗体或抗体构造物通过连接剂连接到TGFβR1抑制剂上。此外,还提供了这些共轭物和组合物的制备方法。